维普中文期刊产品整合服务
35篇 您的检索式:作者名="YOTHER J"
    题名 作者 年代 出处 被引量
1CpsB is a modulator of capsule-associated tyrosine kinase activity in Streptococcus pneumoniae显示文摘BENDER M H YOTHER J 2001The Journal of Biological Chemistry2001,276,47:1
2Novel surface attachment mechanism of the streptococcus pneumoniae protein PspA显示文摘Yother J Johanna MW 1994Infect Immun1994,176,10:1
3Initial safety report of NSABP C-08 :a randomized phase Ⅲ study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage Ⅱ or Ⅲ colon cancer显示文摘Allegra CJ Yothers G O'Connell M J 2009J Clin Oncol2009,27,20:1
4Capsule biosynthesis and bas-ic metabolism in Streptococcus pneumoniae are linked through the cellularphosphoglucomutase显示文摘HARDY G G CAIMANO M J YOTHER J 2000J Bacteriol2000,182,:1
5Positive correlation between tyrosine phosphorylation of CpsD and capsular polysaccharide production in Streptococcus pneumoniae 显示文摘BENDER M H CARTEE R T YOTHER J 2003J Bacteriol2003,185,:1
6Bevacizumab in Stage Ⅱ-Ⅲ Colon Cancer: f-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial显示文摘Allegra CJ Yothers G O'Connell M J 2013Journal of Clinical Oncology2013,31,3:1
7Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon : Results of NSABP Protocol C-08 显示文摘Allegra C J Yothers G 0' Connell M J 2011J Clin Oncol2011,29,1:1
8Requirement for capsule in colonization by Streptococcus pneumoniae显示文摘Magee AD Yother J 2001Infect Immun2001,69,6:1
9FOLFOX and FLOX regimens for the adjuvant treatment of resected stage Ⅱ and Ⅲ colon cancer显示文摘SHARIF S O'CONNELL M J YOTHERS G 2008Cancer Invest2008,26,9:1
10The impact of capecitabine and oxaliplatin in the preoperative muhimodality treatment in patients with carcinoma of the rectum: NSABP R- 04显示文摘Roh MS Yothers GA O'Connell M J 2011J Clin Oncol2011,29,15:1
11Phase III trial assessing bevacizumab in stage II and III carcinoma of the colon: results of NSABP protocol C-08显示文摘Allegra C J Yothers G O'Connell MJ 2011J Clin Onco12011,29,1:1
12Genetics of streptococci, lactococci, and enterococci: review of the sixth international conference 显示文摘Yother J Trieu-cuot P Klaenhammer T R 2002J Bacteriol2002,184,22:1
13Oxaliplatin as adjuvant therapy for colon cancer- updated results of NSABP C-07 trial, including survival and subset analyses 显示文摘Yothers G O'Connell M J Allegra C J 2011J Clin 0ncol2011,29,28:1
14FOLFOX and FLOX regimens for the adjuvant treatment of resected stage Ⅱ and Ⅲ colon cancer显示文摘Sharif S O'Connell M J Yothers G 2008Cancer Invest2008,26,9:1
15Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer显示文摘DIGNAM J J POLITE B N YOTHERS G 2006J Natl Cancer Inst2006,98,22:1
16Genetic alteration of capsule type but not PspA type affects accessibility of surface-bound complement and surface antigens of Streptococcus pneumonia显示文摘Abeyta M Hardy GG Yother J 2003Infect Immun2003,71,1:1
17The impact of capecitabineand oxaliplatin in the preoperative muhimodality treatment in patients with carcinoma of the rectum: NSABP R-04 显示文摘Roh MS Yothers G O'Connell M J 2011J Clin Oncol2011,29,15:1
18Phase Ⅲ trial assessing bevacizumab in stages II and III carcinoma of the colon : Results of NSABP Protocol C-08显示文摘Allegra C J Yothers G O' Connell M J 2011J Clin Oncol2011,29,1:1
19Initial safety report of NSABP C-08, a randomized phase Ⅲ study of modified 5-fluorouracil ( 5-FU )/leucovorin ( LCV ) and oxaliplatin ( OX ) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage Ⅱ/Ⅲ colon cancer显示文摘Allegra C J Yothers G O'Connell M J 2008J Clin Oncol2008,,:1
20Use of two-year disease-free survival (DFS) as a primary endpoint in stage Ⅲ adjuvant colon cancer trials with fluoropyrimidincs with or without oxaliplatin or irinotecan: New data from 12,676 patients from MOSAIC, X- ACT, PETACC-3, NSAPB C-06 and C-07, and C89803显示文摘Sargent D J Yothers G Van Cutsem E 2009J Clin Oncol2009,27,15:1
返回顶部 每页显示:
共2页 首页 上一页 第1页 下一页 末页 /2 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费